Journal ArticleDOI
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Reads0
Chats0
TLDR
Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.About:
This article is published in The Lancet.The article was published on 2019-07-13. It has received 1449 citations till now. The article focuses on the topics: Dulaglutide & Placebo-controlled study.read more
Citations
More filters
Journal ArticleDOI
Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020.
David J. Gladstone,M. Patrice Lindsay,James D. Douketis,Eric E. Smith,Dar Dowlatshahi,Theodore Wein,Aline Bourgoin,Jafna L. Cox,John Falconer,Brett R Graham,Marilyn Labrie,Lena McDonald,Jennifer Mandzia,Daniel Ngui,Paul Pageau,Amanda Rodgerson,William Semchuk,Tammy Tebbutt,Carmen Tuchak,Stephen van Gaal,Karina Villaluna,Norine Foley,Shelagh B. Coutts,Anita D. Mountain,Gord Gubitz,Jacob A. Udell,Rebecca McGuff,Alexandre Y Poppe +27 more
TL;DR: The 2020 update of the Canadian Stroke Best Practice Recommendations (CSBPR) for the Secondary Prevention of Stroke includes current evidence-based recommendations and expert opinions intended for use by clinicians across a broad range of settings as mentioned in this paper.
Journal ArticleDOI
The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
TL;DR: In this article, the authors compared the efficacy and safety of SGLT2i, glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) in terms of cardiovascular outcomes.
Journal ArticleDOI
Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations
TL;DR: In this paper , the authors discuss the epidemiology, phenotypes and pathogenesis of type 2 diabetes mellitus in India and China and evaluate options for optimal pharmacological management. But, the authors do not consider the treatment of T2DM in the Indian and Chinese populations.
Journal ArticleDOI
The future of new drugs for diabetes management
Clifford J. Bailey,Caroline Day +1 more
TL;DR: The future of the newer classes of glucose-lowering drugs, namely dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors, is being redefined by the large prospective cardiovascular outcome trials.
Journal ArticleDOI
Therapie des Typ-2-Diabetes
Rüdiger Landgraf,Jens Aberle,Andreas L. Birkenfeld,B. Gallwitz,Monika Kellerer,Harald Klein,Dirk Müller-Wieland,Michael A. Nauck,H. M. Reuter,E. G. Siegel +9 more
TL;DR: This work presents a probabilistic picture of the immune system’s response to insulin use in the context of a patients with type 2 diabetes.
References
More filters
Journal ArticleDOI
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
TL;DR: The purpose of this study was to develop an equation from MDRD Study data that could improve the prediction of GFR from serum creatinine concentration, and major clinical decisions in general medicine, geriatrics, and oncology are made by using the Cockcroft-Gault formula and other formulas to predict the level of renal function.
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
TL;DR: The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal ArticleDOI
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.
Andrew S. Levey,Josef Coresh,Tom Greene,Lesley A. Stevens,Yaping (Lucy) Zhang,Stephen Hendriksen,John W. Kusek,Frederick Van Lente +7 more
TL;DR: The MDRD Study equation has now been reexpressed for use with a standardized serum creatinine assay, allowing GFR estimates to be reported in clinical practice by using standardized serumcreatinine and overcoming this limitation to the current use of GFR estimating equations.
Journal ArticleDOI
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown-Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse +14 more
TL;DR: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, orNonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.